SCHEMBL17612882

SCHEMBL17612882

CCOC(=O)[C@@H]1CCN(c2ccc(N[S+]([O-])c3cccc4c3ccn4C)c3cccnc23)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 2/20 0.50
▸ KEAP1 Q14145 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ S100A4 P26447 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17612855 0.84 CTSB (0.52) CTSBKEAP1ALDH1A1NPSR1MAPT
SCHEMBL17612907 0.78 KEAP1 (0.48) KEAP1
SCHEMBL17612898 0.74 KEAP1 (0.55) CTSBKEAP1ALDH1A1MAPT
SCHEMBL17599504 0.73 KEAP1 (0.65) KEAP1KDM4EBRD4PRKCAPRKCQ
SCHEMBL17612861 0.70 KEAP1 (0.54) CTSBKEAP1ALDH1A1NPSR1MAPT
SCHEMBL17612856 0.69 KEAP1 (0.56) CTSBKEAP1ALDH1A1NPSR1MAPT
SCHEMBL17612906 0.69 KEAP1 (0.54) CTSBKEAP1ALDH1A1NPSR1MAPT
SCHEMBL17599436 0.68 KEAP1 (0.74) CTSBKEAP1ALDH1A1NPSR1MAPT
SCHEMBL19000157 0.65 CTSB (0.64) CTSBALDH1A1NPSR1MAPTKMT2A
SCHEMBL17599448 0.65 KEAP1 (0.73) CTSBKEAP1ALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997966-A1 Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback